<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7462603\results\search\country\results.xml">
  <result pre="which also blocks viral replication is approved for influenza in" exact="Japan" post="[67] and it is currently in clinical trials for"/>
  <result pre="In 2018, Albuvirtide, a peptide fusion inhibitor, was approved in" exact="China" post="[222]. Within the past decade, the development of peptide-based"/>
  <result pre="(B/E), failed to show sufficient efficacy for approval by the" exact="Thailand" post="Ministry of Health [174]. In 2019, the National Institutes"/>
  <result pre="[49]. The first known case of SARS occurred in southern" exact="China" post="in November 2002 [49]. The disease spread to more"/>
  <result pre="and tested for safety in Phase I clinical trials in" exact="China" post="[123]. Despite the promising safety results, these candidate vaccines"/>
  <result pre="A series of COVID-19 cases were first detected in Wuhan" exact="China" post="in December 2019, WHO declared a global health emergency"/>
  <result pre="2004-20192020CDC 30Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in" exact="the United States" post="â€&quot; 2018â€&quot;2019 Influenza Season2020CDC 31Influenza A Subtypes and the"/>
  <result pre="30Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in the" exact="United States" post="â€&quot; 2018â€&quot;2019 Influenza Season2020CDC 31Influenza A Subtypes and the"/>
  <result pre="HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strainsProc. Natl. Acad. Sci." exact="U. S." post="A.105422008163321633718852475 86HeY.XiaoY.SongH.LiangQ.JuD.ChenX.Design and evaluation of sifuvirtide, a novel HIV-1"/>
  <result pre="silico design to preclinical proof of conceptProc. Natl. Acad. Sci." exact="U. S." post="A.106332009137971380119666568 114KshatriyaR.CachafeiroA.A.KerrR.J.NelsonJ.A.FiscusS.A.Comparison of two rapid human immunodeficiency virus (HIV)"/>
  <result pre="proteins are potent inhibitors of viral fusionProc. Natl. Acad. Sci." exact="U. S." post="A.9351996218621918700906 117LeistnerC.M.Gruen-BernhardS.GlebeD.Role of glycosaminoglycans for binding and infection of"/>
  <result pre="diamond electrode terminated with sialic acid-mimic peptideProc. Natl. Acad. Sci." exact="U. S." post="A.1133220168981898427457924 139McGregorD.P.Discovering and improving novel peptide therapeuticsCurr. Opin. Pharmacol.85200861661918602024"/>
  <result pre="correlation between solution structure and viral inhibitionProc. Natl. Acad. Sci." exact="U. S." post="A.8921199210537105411438243 212WinckelmannA.MorcillaV.ShaoW.SchleimannM.H.HojenJ.F.SchlubT.E.Genetic characterization of the HIV-1 reservoir after Vacc-4x"/>
 </snippets>
</snippetsTree>
